Prevention of Frailty With Fisetin and Exercise in Breast Cancer Survivors
Key claim: A phase II trial is testing whether fisetin plus exercise can prevent frailty in breast cancer survivors by clearing senescent cells.
Abstract
This phase II trial tests how well fisetin and exercise works in preventing frailty in breast cancer survivors. Fisetin is a natural substance found in strawberries and other foods and is available as a nutritional supplement. Nutritional supplements may be useful in eliminating cells that have undergone a process called senescence. Senescence is when a cell ages and permanently stops dividing but does not die. Over time, large numbers of these cells build up in tissues throughout the body and can release harmful substances that cause inflammation and damage nearby healthy cells. Giving fisetin may eliminate senescent cells in patients with breast cancer undergoing physical activity.
Why this matters
Cancer survivors carry an elevated senescent-cell burden from chemotherapy and radiation, making them a high-yield population for testing whether senolytics translate mechanism into clinical frailty prevention. Pairing fisetin with exercise probes whether a natural senolytic can augment a proven physical-function intervention, or whether exercise alone accounts for any benefit — a design contrast that has been missing from most early senolytic trials. Until readout, this is a registered probe, not evidence that fisetin prevents frailty.